InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Explore the complete record of transactions filed by Glickman Marc H., Directeur Exécutif, Directeur Médical. Insider active across 2 companies, notably Hancock Jaffe Laboratories, Inc.. Cumulatively, 4 reports have been published. Total volume traded: €15k. The latest transaction was disclosed on 21 May 2021 — Acquisition. Regulator: SEC (Form 4). The full history is openly available.
Declarations4 total
100,000 shares
Common Stock
SEC:0001493152-21-030333·
100,000 shares
Common Stock
SEC:0001493152-21-030333:0·
€7,7221,600 shares@ €4.826100.0% of flow
Common Stock
SEC:0001493152-21-012878·
Ideal exit: 15 Feb 2022 (T+270)
€7,7221,600 shares@ €4.82650.0% of flow
Common Stock
SEC:0001493152-21-012878:0·
Ideal exit: 15 Feb 2022 (T+270)
4 of 4 declarations
About Glickman Marc H.
Marc H. Glickman is the Executive Vice President and Chief Medical Officer at Hancock Jaffe Laboratories, Inc. and enVVeno Medical Corp. In his roles, he is responsible for medical strategy and the development of new products. Marc Glickman plays a key role in optimizing clinical trials and innovating medical solutions. His expertise in medicine and management is essential for the success of both companies.
